The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.

What Was Tested

The paper reports a study of Angiotensin II Type 1 Receptor Blockers, published as a clinical trial.

The objective of this study was to examine the effects of angiotensin II receptor blocker (ARB), used as an antihypertensive medication, on peritoneal membrane transporters in continuous ambulatory peritoneal dialysis (CAPD) patients.

Who Took Part

The study group was 7 patients.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Prospective and cross-over experimental study of peritoneal membrane transporters was conducted in 7 CAPD patients with hypertension.

The modified peritoneal function tests assessing peritoneal membrane transports were performed at 1) baseline, 2) 6 weeks, 3) 12 weeks following candesartan treatment, and 4) 6 weeks after candesartan withdrawal.

How the Study Was Run

The researchers set it up as a crossover study.

In the crossover set-up each of the patients took both Angiotensin II Type 1 Receptor Blockers and the comparison in turn, acting as their own control.

Hydralazine, which has no effect on peritoneal membrane transports, was added if the target blood pressure was not achieved.

What Was Measured

The subject headings attached to it are Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Benzimidazoles, Biological Transport, Biphenyl Compounds, Blood Pressure and Hypertension.

What This Means in Plain Language

The paper is a crossover study of Angiotensin II Type 1 Receptor Blockers in 7 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2006 (Journal of the Medical Association of Thailand = Chotmaihet thangphaet), a journal based in Thailand.

More context: all human trials.